Document:

Exhibit 10.54

    EXHIBIT
      10.54

    

    

    

    EXECUTIVE
      COMPENSATION ARRANGEMENTS

    

    Listed
      below are the salaries, bonuses and stock option grants for our executive
      officers that were awarded during fiscal 2005 and the salaries that have been
      established for fiscal 2006. Bonuses for fiscal 2006 have not yet been
      determined.

    

    
      	 	 	
              2005

            	 	 	 
	 	 	 	 	 	 	
              Stock
                Option

            	 	
              2006

            	 
	
              Executive
                Officer

            	 	
              Salary

            	 	
              Bonus
                (1)

            	 	
              Grants
                (2)

            	 	
              Salary

            	 
	 	 	 	 	 	 	 	 	 	 
	
              Harvey
                J. Berger, M.D. (3)

            	 	
              $

            	
              504,000

            	 	 	
              ---

            	 	 	
              150,000

            	 	
              $

            	
              544,000

            	 
	
              Chairman
                of the Board of Directors,

              Chief
                Executive Officer and President

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Laurie
                A. Allen, Esq.

            	 	
              $

            	
              288,000

            	 	
              $

            	
              110,000

            	 	 	
              60,000

            	 	
              $

            	
              309,000

            	 
	
              Senior
                Vice President, Legal and Business

              Development,
                Chief Legal Officer and Secretary

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              David
                L. Berstein, Esq.

            	 	
              $

            	
              288,000

            	 	
              $

            	
              110,000

            	 	 	
              60,000

            	 	
              $

            	
              309,000

            	 
	
              Senior
                Vice President, Chief Patent Counsel

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Timothy
                P. Clackson, Ph.D.

            	 	
              $

            	
              290,000

            	 	
              $

            	
              110,000

            	 	 	
              57,500

            	 	
              $

            	
              309,000

            	 
	
              Senior
                Vice President, Chief Scientific Officer

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Edward
                M. Fitzgerald

            	 	
              $

            	
              288,000

            	 	
              $

            	
              110,000

            	 	 	
              60,000

            	 	
              $

            	
              309,000

            	 
	
              Senior
                Vice President, Finance and Corporate

              Operations,
                Chief Financial Officer and Treasurer

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              John
                D. Iuliucci, Ph.D.

            	 	
              $

            	
              290,000

            	 	
              $

            	
              115,000

            	 	 	
              70,000

            	 	
              $

            	
              309,000

            	 
	
              Senior
                Vice President, Chief Development Officer

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Camille
                L. Bedrosian, M.D.

            	 	
              $

            	
              290,000

            	 	
              $

            	
              110,000

            	 	 	
              70,000

            	 	
              $

            	
              309,000

            	 
	
              Vice
                President, Chief Medical Officer

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Richard
                W. Pascoe (4)

            	 	
              $

            	
              61,959

            	 	 	
              ---

            	 	 	
              75,000

            	 	
              $

            	
              275,000

            	 
	
              Vice
                President, Chief Commercial Officer

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 

    

    

    
      	(1)	
              These
                bonuses were awarded and deferred under our 2005 Executive Compensation
                Plan, a non-qualified, unfunded,  deferred compensation
                plan.

            
	 	 
	(2)	
              Stock
                options, except for Mr. Pascoe’s stock options, were granted on October 4,
                2005, have an exercise price of $7.56  per share, which was the fair
                market value of our common stock on the date of grant, and vest 25%
                per
                year over four  years. Mr. Pascoe’s stock options, awarded on
                December 13, 2005 in consideration of his commencement of employment
                with
                the Company, have an exercise price of $6.04 per share, and vest
                25% per
                year over four years.

            
	 	
            
	(3)	
              The
                Board of Directors also awarded 40,000 shares of restricted stock
                to Dr.
                Berger on  December 13, 2005. The fair market value of the stock on
                the date of grant was $6.04 per share. The restricted stock is subject
                to
                repurchase by the Company for $.001 per share if Dr. Berger’s employment
                with the Company is terminated  for cause prior to the thirteen-month
                anniversary of the grant date. The Company’s right of repurchase
                lapses under  certain circumstances, including a change in control of
                the Company and termination of his employment by the  Company other
                than for cause. These terms are subject to the terms of Dr. Berger’s
                employment agreement. The  restricted shares may not be sold,
                transferred, assigned, hypothecated, pledged, encumbered or otherwise
                disposed of  other than to the Company as long as the Company’s right
                of repurchase is in effect.

            
	 	
            
	(4)	
              Mr.
                Pascoe commenced employment with the Company on November 7, 2005
                at an
                agreed-upon annual salary of  $275,000. The amount of salary
                presented for 2005 represents the amount paid to Mr. Pascoe in
                2005.

            

    

     

     

    
      
        
        

      

      
        1Exhibit 10.56

    EXHIBIT
      10.56

    FIFTH
      AMENDMENT TO EMPLOYMENT AGREEMENT

    

    This
      FIFTH
      AMENDMENT TO EMPLOYMENT AGREEMENT (the “ Fifth Amendment") made as of January 1,
      2006 between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the
      "Company"), and Harvey J. Berger, M.D. (the "Employee").

     

    The
      Company and the Employee have entered into an Employment Agreement dated as
      of
      January 1, 1992, as amended as of April 19, 1994, June 30, 1994, January 1,
      1997, and September 2, 2003 (the “Agreement”), and the parties hereto desire to
      further amend certain provisions of the Agreement.

     

    NOW,
      THEREFORE, in consideration of the premises set forth herein and for other
      good
      and valuable consideration, the receipt of which is hereby acknowledged, the
      parties hereto agree to further amend the Agreement as follows: 

     

    I.  Termination
      of Employment.
      The first
      sentence of Section 2 is hereby amended to read as follows:

    

    "The
      term
      of the Employee's employment under this Agreement (the "Term") commenced as
      of
      January 1, 1992 (the “Effective Date”) and shall end on December 31, 2009,
      unless sooner terminated pursuant to Section 4 or 5 of this
      Agreement;”

    

    II. Compensation.
      The
      first sentence of Section 3.1 is hereby amended to read as follows:

    

    “3.1
      As
      full compensation for all services to be rendered pursuant 

    to
      this
      Agreement, the Company agrees to pay the Employee, during the Term, a salary
      at
      the fixed rate of $544,000 per annum during the first year of the term and
      increased each year thereafter as set forth below, payable in equal semi-monthly
      installments, less such deductions or amounts to be withheld as shall be
      required by applicable law and regulations.”

    

    III. Definitions.
      The
      definition of the Company’s “Field of Interest” in Section 16 (c) of the
      Agreement is hereby amended to read as follows:

    

    “The
      Company’s ‘Field of Interest’ means the discovery, development,

    manufacture,
      distribution, and commercialization of any pharmaceutical product that is based
      on or involves (a) intervention in cell signaling, (b) cancer therapy, or (c)
      gene and cell therapy.” 

    

    IV. This
      Fifth
      Amendment shall be governed by and construed and enforced in accordance with
      the
      laws of the Commonwealth of Massachusetts applicable to agreements made and
      to
      be performed entirely in Massachusetts. 

     

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     

     

    V. Except
      as
      modified by this Fifth Amendment, the Agreement remains in full force and effect
      and unchanged.

    

    

    IN
      WITNESS
      WHEREOF, the parties have executed this Fifth Amendment as of the date first
      written above.

     

    
      	 	 	 
	 	
              ARIAD
                PHARMACEUTICALS, INC.

            
	 
 	 
 	 
 
	 	By:  	/s/
              Laurie A.
              Allen 
	 	
              Laurie
                A. Allen, Esq.

            
	 	Corporate
              Secretary 

    

     

    
      	 	 	 
	 	EMPLOYEE
	 
 	 
 	 
 
	 	/s/   	Harvey
              J.
              Berger 
	 	Harvey J. Berger,
              M.D.

    

     

     

    
      
         

      

      
        2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]